Clinical Trial Update: Retrospective Chart Review of Patients With Acanthamoeba Keratitis Who Have Received 0.8 mg/mL Polihexanide as Part of the "Medicines in Special Situations" (Medicamentos en Situaciones Especiales) Program in Spain.

View source ↗

Summary

A retrospective chart review protocol evaluating 0.8 mg/mL polyhexanide for Acanthamoeba keratitis under Spain's Medicines in Special Situations program; the st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acanthamoeba Keratitis

Drugs mentioned

• Polyhexanide (polyhexanide)

Snippet

Sponsor: SIFI SpA | Conditions: Acanthamoeba Keratitis | Status: RECRUITING